BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34666214)

  • 1. Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial.
    Issels RD; Noessner E; Lindner LH; Schmidt M; Albertsmeier M; Blay JY; Stutz E; Xu Y; Buecklein V; Altendorf-Hofmann A; Abdel-Rahman S; Mansmann U; von Bergwelt-Baildon M; Knoesel T
    Eur J Cancer; 2021 Oct; 158():123-132. PubMed ID: 34666214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.
    Issels RD; Lindner LH; Verweij J; Wessalowski R; Reichardt P; Wust P; Ghadjar P; Hohenberger P; Angele M; Salat C; Vujaskovic Z; Daugaard S; Mella O; Mansmann U; Dürr HR; Knösel T; Abdel-Rahman S; Schmidt M; Hiddemann W; Jauch KW; Belka C; Gronchi A;
    JAMA Oncol; 2018 Apr; 4(4):483-492. PubMed ID: 29450452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study.
    Issels RD; Lindner LH; Verweij J; Wust P; Reichardt P; Schem BC; Abdel-Rahman S; Daugaard S; Salat C; Wendtner CM; Vujaskovic Z; Wessalowski R; Jauch KW; Dürr HR; Ploner F; Baur-Melnyk A; Mansmann U; Hiddemann W; Blay JY; Hohenberger P; ;
    Lancet Oncol; 2010 Jun; 11(6):561-70. PubMed ID: 20434400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
    Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
    Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
    Gronchi A; Ferrari S; Quagliuolo V; Broto JM; Pousa AL; Grignani G; Basso U; Blay JY; Tendero O; Beveridge RD; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P; Casali PG
    Lancet Oncol; 2017 Jun; 18(6):812-822. PubMed ID: 28499583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
    Denkert C; von Minckwitz G; Darb-Esfahani S; Lederer B; Heppner BI; Weber KE; Budczies J; Huober J; Klauschen F; Furlanetto J; Schmitt WD; Blohmer JU; Karn T; Pfitzner BM; Kümmel S; Engels K; Schneeweiss A; Hartmann A; Noske A; Fasching PA; Jackisch C; van Mackelenbergh M; Sinn P; Schem C; Hanusch C; Untch M; Loibl S
    Lancet Oncol; 2018 Jan; 19(1):40-50. PubMed ID: 29233559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy.
    Goto W; Kashiwagi S; Asano Y; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    ESMO Open; 2018; 3(6):e000305. PubMed ID: 30233820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.
    Shang M; Chi Y; Zhang J; Chang J; Yang H; Yin S; Tan Q; Man X; Li H
    Front Oncol; 2021; 11():706606. PubMed ID: 35070953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy and regional hyperthermia for high-risk adult-type soft tissue sarcomas.
    Lindner LH; Blay JY; Eggermont AMM; Issels RD
    Eur J Cancer; 2021 Apr; 147():164-169. PubMed ID: 33684876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy plus radiation versus chemotherapy plus regional hyperthermia in high-grade soft tissue sarcomas: a retrospective comparison.
    Zschaeck S; Wust P; Melcher I; Nadobny J; Rau D; Striefler J; Pahl S; Flörcken A; Kunitz A; Ghadjar P
    Int J Hyperthermia; 2018; 35(1):1-9. PubMed ID: 30300018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a subgroup analysis of a randomized phase-III multicenter study.
    Angele MK; Albertsmeier M; Prix NJ; Hohenberger P; Abdel-Rahman S; Dieterle N; Schmidt M; Mansmann U; Bruns CJ; Issels RD; Jauch KW; Lindner LH
    Ann Surg; 2014 Nov; 260(5):749-54; discussion 754-6. PubMed ID: 25379845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis.
    Orhan A; Vogelsang RP; Andersen MB; Madsen MT; Hölmich ER; Raskov H; Gögenur I
    Eur J Cancer; 2020 Jun; 132():71-84. PubMed ID: 32334338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
    Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
    Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives.
    Seifert G; Budach V; Keilholz U; Wust P; Eggert A; Ghadjar P
    Radiat Oncol; 2016 Apr; 11():65. PubMed ID: 27138749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC.
    Kaewkangsadan V; Verma C; Eremin JM; Cowley G; Ilyas M; Eremin O
    BMC Cancer; 2018 Feb; 18(1):123. PubMed ID: 29390966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.